Taysha Gene Therapies, Inc. $TSHA Shares Purchased by Octagon Capital Advisors LP

Key Points

• Octagon Capital Advisors LP increased its stake in Taysha Gene Therapies by 2.4%, acquiring an additional 250,000 shares, now holding around 10.7 million shares worth approximately $14.87 million.
• Several institutions have shown increased investments in Taysha, with notable increases from HSBC (65.6%) and Jane Street Group (57.6%) during the fourth quarter.
• Analysts have positive outlooks for Taysha Gene Therapies, with multiple firms raising their price targets, resulting in an average target price of $8.29 and an overall "Buy" rating from eight investment analysts.

Octagon Capital Advisors LP boosted its holdings in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA - Free Report) by 2.4% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 10,700,000 shares of the company's stock after purchasing an additional 250,000 shares during the period. Taysha Gene Therapies comprises approximately 1.6% of Octagon Capital Advisors LP's investment portfolio, making the stock its 12th biggest holding. Octagon Capital Advisors LP owned approximately 5.22% of Taysha Gene Therapies worth $14,873,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Granahan Investment Management LLC lifted its position in Taysha Gene Therapies by 0.3% during the first quarter. Granahan Investment Management LLC now owns 1,640,793 shares of the company's stock valued at $2,281,000 after purchasing an additional 4,412 shares during the period. Hsbc Holdings PLC lifted its position in Taysha Gene Therapies by 65.6% during the fourth quarter. Hsbc Holdings PLC now owns 20,391 shares of the company's stock valued at $36,000 after purchasing an additional 8,076 shares during the period. Rhumbline Advisers lifted its position in Taysha Gene Therapies by 7.0% during the first quarter. Rhumbline Advisers now owns 205,462 shares of the company's stock valued at $286,000 after purchasing an additional 13,383 shares during the period. ProShare Advisors LLC raised its position in shares of Taysha Gene Therapies by 32.3% in the fourth quarter. ProShare Advisors LLC now owns 59,076 shares of the company's stock worth $102,000 after acquiring an additional 14,418 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Taysha Gene Therapies by 23.3% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 108,604 shares of the company's stock worth $188,000 after acquiring an additional 20,551 shares during the period. 77.70% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Taysha Gene Therapies

In other news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction that occurred on Wednesday, September 10th. The shares were sold at an average price of $3.23, for a total value of $646,000.00. Following the completion of the sale, the insider owned 1,006,439 shares of the company's stock, valued at $3,250,797.97. This represents a 16.58% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. 3.78% of the stock is currently owned by company insiders.

Taysha Gene Therapies Price Performance

Shares of TSHA traded down $0.17 during mid-day trading on Friday, hitting $3.07. 4,421,627 shares of the company were exchanged, compared to its average volume of 3,382,718. Taysha Gene Therapies, Inc. has a 1-year low of $1.05 and a 1-year high of $3.40. The company has a debt-to-equity ratio of 0.17, a quick ratio of 12.48 and a current ratio of 12.48. The company has a 50 day moving average of $2.81 and a 200-day moving average of $2.32. The stock has a market cap of $837.50 million, a price-to-earnings ratio of -9.03 and a beta of 0.98.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 12th. The company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.02). Taysha Gene Therapies had a negative net margin of 1,144.97% and a negative return on equity of 78.44%. The business had revenue of $1.99 million for the quarter, compared to analysts' expectations of $1.61 million. Analysts expect that Taysha Gene Therapies, Inc. will post -0.35 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on TSHA. Bank of America began coverage on shares of Taysha Gene Therapies in a research report on Friday, July 11th. They issued a "buy" rating and a $8.00 price objective for the company. JMP Securities upped their price objective on shares of Taysha Gene Therapies from $5.00 to $6.00 and gave the stock a "market outperform" rating in a research report on Thursday, May 29th. Chardan Capital upped their price objective on shares of Taysha Gene Therapies from $9.00 to $10.00 and gave the stock a "buy" rating in a research report on Tuesday, August 12th. Wells Fargo & Company upped their price objective on shares of Taysha Gene Therapies from $7.50 to $8.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 13th. Finally, Needham & Company LLC reiterated a "buy" rating and issued a $8.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, July 1st. Eight research analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, Taysha Gene Therapies has an average rating of "Buy" and a consensus price target of $8.29.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.